Search
forLearn
5 / 801 resultslearn Vascular Endothelial Growth Factor
learn Epidermal Growth Factor
learn Pea peptides
learn oligopeptide-71
Research
5 / 741 resultsresearch The seasonal development dynamics of the yak hair cycle transcriptome
Yak hair growth is influenced by genes and hormones, helping them adapt to alpine environments.
research Genome-wide detection and sequence conservation analysis of long non-coding RNA during hair follicle cycle of yak
Researchers found that certain RNA sequences play a role in yak hair growth and these sequences are somewhat similar to those in cashmere goats.
research Molecular mechanism of polygonum multiflorum in the treatment of androgenic alopecia: based on bioinformatics and molecular docking method
Polygonum multiflorum may treat hair loss by reducing inflammation and stress, and boosting melanin.
research Transcriptome analysis reveals the genetic basis underlying the development of skin appendages and immunity in hedgehog (Atelerix albiventris)
The study found that certain genes are important for hedgehog skin appendage development and immunity, with spines possibly evolving for protection and infection resistance.
research Discovery and Comprehensive Analysis of miRNAs from Liaoning Cashmere Goat Skin during Anagen
Certain miRNAs are linked to Cashmere goat hair quality.
Community Join
5 / 1000+ resultscommunity KX-826 Phase II Results Just Dropped (Male AGA) – Key Takeaways
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community Kintor has announced the results for their human Phase I trials of GT20029
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
community Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia
Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.